



## Clinical trial results:

### The use of GnRH antagonist versus co-flare protocol for women with low ovarian reserve undergoing first cycle of in vitro fertilization

#### Summary

EudraCT number	2012-004824-39
Trial protocol	GB
Global end of trial date	31 December 2016

#### Results information

Result version number	v1 (current)
This version publication date	20 February 2020
First version publication date	20 February 2020

#### Trial information

##### Trial identification

Sponsor protocol code	EDGE ID 34459
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	University Hospitals of Leicester NHS Trust
Sponsor organisation address	Infirmity Road, Leicester, United Kingdom, LE1 5WW
Public contact	Mr Gelbaya, University Hospitals of Leicester NHS Trust, tarek.gelbaya@uhl-tr.nhs.uk
Scientific contact	Mr Gelbaya, University Hospitals of Leicester NHS Trust, tarek.gelbaya@uhl-tr.nhs.uk

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 December 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 December 2016
Global end of trial reached?	Yes
Global end of trial date	31 December 2016
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To compare the effect of two different treatment protocols of ovarian stimulation for IVF on the number of eggs retrieved from women with low ovarian reserve undergoing their first IVF cycle: the co-flare protocol and the GnRH-antagonist protocol.

Protection of trial subjects:

Ethics favourable opinion will be obtained from an appropriate committee. The Trust R & D approval is mandatory.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 September 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 4
Worldwide total number of subjects	4
EEA total number of subjects	4

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants

We aim to recruit 60 women with low serum AMH (3.08-21.97 pmol/l) who are about to start their first IVF treatment cycle.

Randomisation procedure

Central randomisation will be employed and coordinated by the trial statistician (from Quanticate, an independent clinical research organisation) who will not be involved in patients' rec

### Pre-assignment

Screening details:

- Women 23-39 years, with body mass index (BMI) of 19-30 Kg/m<sup>2</sup>, who are ready to start their first IVF treatment cycle with or without ICSI, with serum FSH between 10 and 14.99, who were subsequently found to have low AMH (3.08-21.97 pmol/L). (These AMH levels are compatible with low ovarian reserve on Gen II assay results)

### Period 1

Period 1 title	Recruitment overall period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

participants are allocated to 1 of 2 treatment arms using the central allocation system.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Arm 1

Arm description:

The short agonist protocol

Arm type	Experimental
Investigational medicinal product name	buserelin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Daily dose of 500mcg administered subcutaneous

<b>Arm title</b>	Arm 2
------------------	-------

Arm description:

The antagonist protocol

Arm type	Active comparator
Investigational medicinal product name	Cetrotide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

daily dose of 0.25mg administered by subcutaneous injection

<b>Number of subjects in period 1</b>	Arm 1	Arm 2
Started	2	2
Completed	1	0
Not completed	1	2
withdrawn prior to dosing	1	1
withdrawn prior to randomisation	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	Recruitment overall period
-----------------------	----------------------------

Reporting group description: -

Reporting group values	Recruitment overall period	Total	
Number of subjects	4	4	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	4	4	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
females between the ages of 23-39			
Units: Subjects			
Female	4	4	
Not recorded	0	0	

### Subject analysis sets

Subject analysis set title	recruitment
----------------------------	-------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:  
number of subjects recruited

Reporting group values	recruitment		
Number of subjects	1		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	4		
From 65-84 years	0		
85 years and over	0		

Gender categorical			
females between the ages of 23-39			
Units: Subjects			
Female	4		
Not recorded	0		

---

## End points

### End points reporting groups

Reporting group title	Arm 1
Reporting group description: The short agonist protocol	
Reporting group title	Arm 2
Reporting group description: The antagonist protocol	
Subject analysis set title	recruitment
Subject analysis set type	Per protocol
Subject analysis set description: number of subjects recruited	

### Primary: Live birth

End point title	Live birth <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe: 40 weeks of pregnancy/ 10 months where dosed	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Minimal recruitment to the study. 4 subjects in total. Of these three subjects withdrew prior to dosing. No analysis undertaken.

End point values	Arm 1	Arm 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[2]</sup>	0 <sup>[3]</sup>		
Units: 40 weeks of pregnancy				
number (not applicable)				

Notes:

[2] - Minimal recruitment with only one subject randomised. No analysis undertaken

[3] - 3 subjects withdrew prior to dosing

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

10 months

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

### Reporting groups

Reporting group title	the antagonist protocol
-----------------------	-------------------------

Reporting group description: -

Reporting group title	The short agonist protocol
-----------------------	----------------------------

Reporting group description: -

Serious adverse events	the antagonist protocol	The short agonist protocol	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	the antagonist protocol	The short agonist protocol	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No non-serious adverse events were reported for this trial.



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported